GLP-1 Agonists: Reading the Evidence Carefully
The trials behind semaglutide and tirzepatide are among the best-designed in recent pharmaceutical history — and they still require careful reading to understand what they actually show versus what the headlines report.
GLP-1 Agonists and the Musculoskeletal System
Semaglutide and tirzepatide produce dramatic weight loss — and a clinically significant portion of that loss comes from muscle, not fat. For active patients and those concerned with long-term function, this metabolic trade-off has orthopedic implications that most prescribers are not discussing.